There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eiger Biopharmaceuticals (EIGR – Research Report) and Magenta Therapeutics (MGTA – Research Report) with bullish sentiments.
Eiger Biopharmaceuticals (EIGR)
In a report issued on December 12, Robert Hazlett from BTIG maintained a Buy rating on Eiger Biopharmaceuticals, with a price target of $9.00. The company’s shares closed last Tuesday at $1.28, close to its 52-week low of $0.96.
According to TipRanks.com, Hazlett is a 3-star analyst with an average return of
Eiger Biopharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.50, representing a 400.0% upside. In a report issued on December 9, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
Magenta Therapeutics (MGTA)
BTIG analyst Yun Zhong reiterated a Buy rating on Magenta Therapeutics yesterday and set a price target of $6.00. The company’s shares closed last Tuesday at $1.06, close to its 52-week low of $0.92.
According to TipRanks.com, Zhong has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Magenta Therapeutics with a $6.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EIGR:
- Biotech Alert: Searches spiking for these stocks today
- Eiger BioPharmaceuticals price target lowered to $9 from $48 at BTIG
- Eiger BioPharmaceuticals price target lowered to $3 from $29 at Baird
- Eiger BioPharmaceuticals price target lowered to $4 from $23 at Citi
- Eiger Biopharmaceuticals Plunges 70% on New Phase 3 Data
